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(Top) The iMSaT team attends barazas (community meetings organized by 
the village chief ) to explain iMSaT, test the people who attend, and treat those 
who are infected. (Below) A health worker visits a home to test residents for 
malaria and treat those infected.
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CDC Tests New Interventions
In the last decade, currently available malaria 
interventions have dramatically decreased the number 
of deaths and cases of malaria, but to take the next 
step toward eliminating malaria, new interventions 
are needed. One new intervention that CDC is 
piloting,  intermittent mass screen and treat (iMSaT), 
involves testing all people living in areas with malaria 
transmission and then providing treatment to people 
infected with the malaria parasite. Once they are 
treated, their blood no longer contains parasites and 
cannot infect the mosquitoes that bite them. If iMSaT is 
effective, it may be scaled up countrywide and beyond. 
CDC is evaluating other interventions, such as mass drug 
administration, to stay ahead of the parasite. 
For more than 60 years, the Centers for Disease Control and 
Prevention (CDC) has been a leader in the fight against malaria 
since successfully eliminating it in the United States. Building 
on that success, CDC experts continue to develop and evaluate 
malaria control interventions to reduce malaria illness and 
death and ultimately to eliminate malaria globally. CDC’s 
strategic research helped develop and evaluate each of the 
effective tools now used throughout the world to prevent and 
control malaria: 
 • Insecticide-treated bed nets (ITNs)
 • Intermittent preventive treatment for pregnant  
women (IPTp) 
 • Improved management of malaria illness with rapid 
diagnostic tests (RDTs) and artemisinin-containing 
combination therapies (ACTs) 
 • Indoor residual spraying (IRS) 
Massive scale-up of these proven interventions in the last 
decade has led to unprecedented gains in the fight against 
malaria. From 2000 to 2012, 3.3 million lives were saved 
globally, and malaria deaths in Africa were cut nearly in half.
The Changing Malaria Landscape Calls 
for New Tools and Approaches
Now, in countries with high malaria transmission where 
interventions have reached high levels of coverage, the 
number of people ill or dying from malaria has decreased. 
Even so, the numbers  remain unacceptably high. In many 
places, success in controlling malaria has changed malaria 
transmission patterns so that some areas have almost no 
malaria. In addition, in much of Africa, the mosquito that 
transmits malaria is not killed or repelled by the insecticides 
being used, and in Asia, the malaria parasite is becoming 
resistant to artemisinin, the principal component of the 
combination treatments that are used to treat malaria 
worldwide. If the past is an indicator, resistance to these 
life-saving antimalarials will spread to Africa.  Success and 
resistance are creating a malaria landscape that requires new 
tools and approaches.
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CDC is actively conducting research  to develop and evaluate 
innovative cutting-edge tools so that malaria efforts can 
continue to save lives and reach the goal of elimination. 
Examples include iMSaT (box), as well as:
 • LAMP: Development of a field-ready, point-of-care 
molecular diagnostic assay device based on CDC’s 
recent work to improve detection of malaria parasite 
DNA. This device, unlike an RDT, will be able to detect 
low-level infections in healthy people who go on to 
infect mosquitoes and sustain transmission of malaria 
in endemic areas. 
 • Durable wall liners 
(DLs): These thin 
sheets treated  
with insecticides 
mimic the effect 
of IRS. CDC has 
evaluated the 
added benefit of 
DLs, when used 
together with 
ITNS, in Kenya, and 
will soon begin a 
study in Malawi. 
Preliminary analysis from Kenya indicated that the 
added benefit of DLs to ITNs  
was a reduction in the incidence of new malaria 
infections by 38% among all household members.
 • Spatial repellents are chemicals that repel  
mosquitoes and may be useful for outdoor-biting 
mosquitoes that transmit malaria.  ITNs and IRS 
primarily provide protection against mosquitoes  
that bite indoors. We are beginning an evaluation  
of the use of these repellents in Kenya.
 • Vaccine: CDC is evaluating a malaria candidate  
vaccine, RTS,S/AS01, in Siaya, Kenya, one of 11  
Phase III trial sites. Over 18 months, the vaccine 
prevented 941 cases per 1,000 children vaccinated 
and 444 cases per 1,000 infants vaccinated. Vaccine 
effectiveness was even higher at the KEMRI/CDC site  
in Siaya, where transmission was more intense.
Surveillance, Monitoring, and 
Evaluation 
CDC is working to determine the most efficient ways to 
track the progress of malaria control and elimination, 
identify setbacks, and respond rapidly when needed, 
as well as to determine how such tools can be used 
to measure public health impact. For example, in 
Zanzibar, in collaboration with the Ministry of Health and 
Social Welfare, CDC, as part of the President’s Malaria 
Initiative, embarked on a public–private partnership 
with a telecommunications provider to develop a next-
generation surveillance system that communicates in 
real time weekly confirmed malaria cases. If an unusual 
increase is detected, a rapid response is begun.
Investment in monitoring and evaluation systems not 
only provides the data needed to measure the impact of 
the U.S. Government’s malaria control investments, but 
also builds local capacity—necessary for the long-term 
success of malaria control efforts. CDC has supported 
many public health workers to obtain advanced degrees 
and certificates, including PhDs and masters’ degrees. 
Their ability to conduct research and interpret results helps 
provide the evidence base for programmatic decisions.
A Congressional Mandate 
Recognizing CDC’s strengths, Congress under the 
Lantos-Hyde Act directed CDC to “advise the U.S. Global 
Malaria Coordinator on priorities for operations and 
implementation research” and “on monitoring, surveillance, 
and evaluation activities” and “to be a key implementer 
of such activities.” CDC fulfills this role by implementing 
the U.S. President’s Malaria Initiative with USAID and by 
focusing our expertise to produce critical evidence on  
new tools and strategies to impact malaria globally.
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